Laboratory Developed Tests Market Size & Growth Forecast 2027–2036, By Segments (Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Laboratory Developed Tests Market size was worth USD 15.1 billion in 2026 and is expected to grow at a 6.94% CAGR between 2027 and 2036, crossing USD 29.54 billion by 2036. The industry revenue for 2027 is calculated at USD 15.98 billion.
Get more details on this report
Request Free Sample ReportLaboratory Developed Tests Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 39.78% of the market in 2026 due to its advanced laboratory infrastructure, strong molecular testing capabilities, and widespread use of specialized diagnostics across clinical care settings.
- Asia Pacific is expected to grow at an 8.02% CAGR as healthcare systems expand laboratory capabilities, increase molecular testing adoption, and improve access to specialized diagnostic services.
Segment Momentum
- Oncology held a 23.92% share in 2026 because laboratories rely on highly tailored testing for cancer detection, characterization, and treatment monitoring, sustaining strong demand for specialized diagnostic solutions.
- Immunoassays are the fastest-growing technology segment as laboratories adopt scalable, workflow-friendly testing methods that support broad biomarker detection with greater operational flexibility.
Market Expansion Drivers
- Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand.
- Expansion of personalized medicine and precision oncology driving advanced test utilization.
- AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency.
Leading Market Participants
- Top companies in the laboratory developed tests market include Illumina, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics Incorporated (United States), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), QIAGEN N.V. (Germany), Guardant Health, Inc. (United States), NeoGenomics, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Exact Sciences Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 15.1 billion
- 2027 Estimated Market Size: USD 15.98 billion.
- Projected Market Size: USD 29.54 billion by 2036
- Growth Forecast: 6.94% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Molecular Diagnostics (Technology) | Oncology (Application)
- Emerging Opportunity Segment: Immunoassays (Technology) | Nutritional & Metabolic Disease (Application)
Market Growth Drivers and Industry Trends
Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand
The growing prevalence of cancer and genetic disorders is increasing the need for specialized diagnostic approaches, supporting laboratory developed tests market growth as healthcare providers seek more adaptable testing options for complex conditions. Laboratories can develop and modify tests to address emerging biomarkers, uncommon genetic abnormalities, and disease-specific diagnostic requirements that may not be adequately covered by standardized testing methods. Rising awareness of early disease detection is also encouraging clinicians to pursue more comprehensive diagnostic evaluations, while the increasing complexity of cancer biology is creating demand for assays capable of identifying clinically relevant molecular characteristics. Greater diagnostic attention to inherited and acquired disorders further expands the range of applications for laboratory-developed testing across hospitals, reference laboratories, and specialized diagnostic facilities.
Expansion of personalized medicine and precision oncology driving advanced test utilization
The growing adoption of individualized treatment strategies is creating a stronger role for laboratory developed tests market applications, particularly as physicians increasingly require detailed molecular information to guide therapy selection. Precision oncology depends on identifying specific genetic mutations, biomarkers, and other biological characteristics that can influence how patients respond to targeted treatments, creating demand for specialized assays that can be adapted to evolving clinical requirements. In personalized medicine, diagnostic testing is also becoming more closely integrated with treatment decisions rather than serving solely as a means of confirming disease. This shift encourages laboratories to develop sophisticated testing capabilities for patient stratification, treatment monitoring, and identification of clinically meaningful molecular profiles, while the expanding range of therapeutic targets continues to broaden testing requirements.
AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency
Integration of artificial intelligence with genomic sequencing and laboratory automation is strengthening laboratory developed tests market growth by improving the ability of diagnostic laboratories to process, interpret, and manage increasingly complex testing workflows. AI-based analytical tools can assist with the identification of genetic patterns and interpretation of large volumes of sequencing information, helping laboratories handle data-intensive diagnostic procedures more efficiently. At the same time, automated sample preparation, processing, and reporting systems can reduce manual intervention and support greater consistency across testing operations. These technologies are particularly valuable as laboratories encounter growing demand for molecular and genomic analyses, since streamlined workflows allow specialized facilities to manage complex assays while maintaining operational efficiency and reducing bottlenecks associated with manual diagnostic processes.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand | 2.20% | High | North America, Europe | High | Near Term |
| Expansion of personalized medicine and precision oncology driving advanced test utilization | 2.00% | High | North America, Europe, Asia Pacific | High | Mid Term |
| AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency | 1.60% | Moderate | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held a 39.78% share of the laboratory developed tests market in 2026, supported by sophisticated clinical laboratory infrastructure, strong diagnostic capabilities, and established adoption of specialized testing services. The region's advanced healthcare system creates demand for highly targeted diagnostic approaches, particularly where conventional testing options may not fully address complex clinical requirements. Continued investment in precision medicine, molecular diagnostics, and personalized healthcare is also expanding the role of laboratory-developed testing across specialized medical applications. Strong laboratory expertise, established quality practices, and increasing demand for individualized diagnostic information further reinforce North America's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing diagnostic awareness, and growing adoption of advanced laboratory technologies. As healthcare systems modernize, laboratories are gaining greater access to molecular, genomic, and specialized diagnostic capabilities, creating opportunities for laboratory-developed tests in complex disease assessment. Rising healthcare expenditure and increasing demand for personalized treatment approaches are also supporting market development. The expansion of clinical laboratory networks and growing investment in diagnostic research are helping broaden access to specialized testing across both established and emerging healthcare markets.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Diagnostic StandardsGermany emphasizes laboratory developed tests that support precision diagnostics while maintaining rigorous analytical validation and quality requirements. German laboratories continue expanding advanced molecular testing capabilities across oncology, infectious diseases, and genetic diagnostics.
France 🇫🇷
Specialized Diagnostic ServicesFrance supports laboratory developed tests through collaboration between hospital laboratories, research institutions, and diagnostic developers. French laboratories continue refining specialized assays that address complex clinical conditions while supporting broader adoption of precision healthcare.
Italy 🇮🇹
Laboratory Capacity EnhancementItaly is strengthening laboratory developed tests by modernizing diagnostic infrastructure and expanding access to advanced molecular testing. Clinical laboratories in Italy emphasize standardized workflows, improved analytical performance, and specialized testing services for complex disease management.
Japan 🇯🇵
Clinical Testing InnovationJapan prioritizes laboratory developed tests that enhance diagnostic precision and support individualized treatment decisions. Healthcare providers in Japan increasingly adopt advanced molecular technologies and automated laboratory workflows to improve testing efficiency and clinical utility.
South Korea 🇰🇷
Molecular Testing CapabilitySouth Korea is expanding laboratory developed tests through investments in advanced clinical laboratories and biotechnology innovation. Organizations strengthen genomic testing capabilities and specialized diagnostic services to support precision medicine across multiple therapeutic areas.
United States 🇺🇸
Precision Diagnostics ExpansionThe U.S. laboratory developed tests market continues evolving through increasing demand for personalized medicine, molecular diagnostics, and specialized clinical testing. Laboratories in the U.S. invest in advanced assay development, automation, and data analytics to improve diagnostic accuracy and efficiency.
Segment Leadership and Growth Trends
Laboratory Developed Tests Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Molecular Diagnostics (Largest Segment) vs Immunoassays (Fastest-Growing Segment)
Molecular diagnostics accounted for the largest share of the laboratory developed tests market at 27.79% in 2026, reflecting their strong role in identifying diseases through sensitive and highly specific analysis of genetic and molecular biomarkers. These tests are widely valuable in areas requiring precise disease characterization, pathogen detection, and personalized clinical assessment. Continued advances in molecular testing technologies, increasing emphasis on early and accurate diagnosis, and broader demand for specialized laboratory testing are reinforcing the importance of molecular diagnostics within laboratory-developed testing.
Immunoassays are emerging as the fastest-growing technology segment, supported by their broad applicability across diagnostic testing and their ability to detect a wide range of proteins, hormones, antibodies, and other biomarkers. Growing demand for accessible and efficient testing across diverse clinical applications is encouraging wider use of immunoassay-based laboratory-developed tests. Improvements in assay sensitivity, automation, and workflow efficiency, together with increasing demand for biomarker-driven diagnosis and monitoring, are creating favorable conditions for continued segment expansion.
Application Segment Analysis: Oncology (Largest Segment) vs Nutritional & Metabolic Disease (Fastest-Growing Segment)
Holding the largest share of the laboratory developed tests market at 23.92% in 2026, the oncology segment benefits from the increasing need for precise cancer detection, characterization, and treatment monitoring. Laboratory-developed tests support oncology care by enabling analysis of tumor-related biomarkers and molecular characteristics that can guide clinical decision-making. The growing emphasis on personalized medicine, earlier disease identification, and more targeted therapeutic strategies is increasing demand for specialized diagnostic testing throughout the cancer care pathway.
Nutritional and metabolic disease represents the fastest-growing application segment, driven by rising attention to metabolic health, nutritional deficiencies, and conditions requiring ongoing biomarker monitoring. Laboratory-developed testing can provide clinicians with detailed insights into biochemical and metabolic parameters, supporting individualized assessment and disease management. Increasing awareness of preventive healthcare, greater emphasis on early identification of metabolic abnormalities, and the expanding role of laboratory testing in personalized care are contributing to stronger demand in this application area.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Immunoassays, Hematology & Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy, Others | Molecular Diagnostics | Immunoassays |
| Application | Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Immunology, Endocrine, Nutritional & Metabolic Disease, Cardiology, Mental/Behavioral Disorder, Pediatrics-specific Testing, Hematology/General Blood Testing, Bodily Fluid Analysis, Toxicology, Others | Oncology | Nutritional & Metabolic Disease |
Competitive Landscape and Market Positioning
Leading companies in the laboratory developed tests market:
1. Illumina Inc. (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Quest Diagnostics Incorporated (United States)
4. Abbott Laboratories (United States)
5. Siemens Healthineers AG (Germany)
6. QIAGEN N.V. (Germany)
7. Guardant Health Inc. (United States)
8. NeoGenomics Inc. (United States)
9. Thermo Fisher Scientific Inc. (United States)
10. Exact Sciences Corporation (United States)
The laboratory developed tests market is expanding due to increasing demand for personalized diagnostics and advanced clinical testing. Innovation in testing methodologies is improving diagnostic accuracy. The laboratory developed tests market is also influenced by regulatory frameworks guiding test validation and deployment.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| Guardant Health Inc. (United States) | |||||||
| NeoGenomics Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Exact Sciences Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Plus Therapeutics | Aug-25 | Plus Therapeutics secured College of American Pathologists (CAP) accreditation for its CNSide Diagnostics clinical laboratory. This milestone, which complements existing CLIA certification, enhances the firm’s quality assurance framework and supports the commercial rollout of its CNSide cerebrospinal fluid assay platform within the specialized central nervous system diagnostic testing market. |
| PrecisionLife & Ovation.io | Aug-25 | PrecisionLife and Ovation.io announced a collaboration to develop laboratory-developed and direct-to-consumer genetic tests tailored to predict patient responses to GLP-1 therapies. This initiative underscores the increasing convergence of precision medicine and predictive diagnostics, aiming to optimize therapeutic matching and improve clinical outcomes through data-driven genomic testing. |
| Becton Dickinson | Jul-25 | Becton Dickinson expanded its BD MAX diagnostic platform menu in Europe by integrating two IVDR-certified Viasure assays. This enhancement strengthens the company’s molecular diagnostics portfolio under stringent European regulatory standards, promoting greater clinical adoption of automated, high-throughput laboratory testing solutions for infectious disease management. |
| Roche | Jul-25 | Roche launched updated cobas 6800/8800 version 2.0 systems and associated software following recent regulatory clearance. These upgrades significantly improve high-throughput molecular testing performance and workflow efficiency, reinforcing the company’s competitive position in providing automated laboratory infrastructure for infectious disease and clinical diagnostic applications. |
| Pictor | Jul-25 | Pictor established its U.S. headquarters in California, a strategic move to accelerate the commercialization of its multiplex proteomics diagnostic platform. The expansion increases the availability of the company’s high-performance testing technology in the North American market and strengthens its operational footprint within the life sciences diagnostics ecosystem. |
| LabGenomics USA | Jun-25 | LabGenomics USA expanded its U.S. clinical diagnostics network through the acquisition of Integrated Molecular Diagnostics laboratories. By increasing its portfolio to four CLIA-certified facilities, the company has significantly bolstered its laboratory testing capacity and enhanced its ability to scale molecular diagnostic services across the domestic clinical market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Laboratory Developed Tests Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| End User | Hospital Laboratories, Independent Diagnostic Laboratories, Academic & Research Laboratories, Physician Office Laboratories |
| Sample Type | Blood & Serum, Urine, Tissue & Biopsy, Saliva & Other Body Fluids |
| Reimbursement Status | Reimbursed Tests, Partially Reimbursed Tests, Self-Pay Tests, Research/Institution-Funded Tests |
Laboratory Developed Tests Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Opportunity Assessment |
|
| Regulatory Pathway Evolution Analysis |
|
| Reimbursement & Market Access Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow big is the laboratory developed tests market?
What is the expected industry size of laboratory developed tests by 2036?
How is the shift toward precision oncology and personalized medicine driving adoption in the laboratory developed tests market?
How are AI-enabled sequencing and laboratory automation improving efficiency in the laboratory developed tests market?
Why is Oncology the largest application segment in the laboratory developed tests market?
Which technology segment is growing the fastest in the laboratory developed tests market?
Why is North America the leading laboratory developed tests market?
What is driving laboratory developed tests market growth in Asia Pacific?
Who are the major participants shaping the laboratory developed tests landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization